This mechanistic review examined the pharmacological actions of classic and emerging cannabinoid receptors on the renal system to identify potential therapeutic targets for kidney disease.
Abstract
Chronic kidney disease (CKD) is a significant health problem around the world. It can progress towards end-stage renal disease (ESRD), in which the current therapeutic options are dialysis and kidney transplant, which have several challenges in therapy compliance and finding a donor. There is a crosstalk between high blood pressure, diabetes, and obesity, which are the leading causes of CKD. The increased prevalence of these conditions, plus the ageing population, highlights the importance of finding new therapies to prevent and stop the progression of CKD. At the cellular level, CKD is characterized by the progressive loss of podocytes in the kidney glomeruli, reducing their filtration capacity. Other hallmarks of CKD are also part of acute kidney injury (AKI) pathogenesis, and both conditions are interlinked. The renal system expresses cannabinoid receptor types 1 and 2 (CB1 and CB2, respectively). There is evidence in animal models that targeting the cannabinoid receptors could modulate the progression of CKD and AKI. The role of cannabinoid signalling has not been sufficiently explored; several receptors that are not fully characterized have emerged as putative cannabinoid receptors (i.e., GPR55, GPR18, and GPR119), and some have been implicated in kidney pathophysiology. Moreover, cannabinoid receptors also interact and/or regulate other receptors (e.g., AT1, TRPV1, and PPARγ). Thus, there are several open questions regarding the role that cannabinoid signalling may play in the context of kidney diseases. In this mechanistic review, we examined the pharmacological actions of classic and emerging cannabinoid receptors on the renal system to identify potential therapeutic targets for kidney disease.
This review summarizes the major pathogenic mechanisms of DKD and advances in Western and Chinese medical treatment, with the aim of providing a reference for clinical prevention and management.
Xiao-Duo Ai, Gen-Ping Lei· Journal of Artificial Intell...· 0 citations
Investigating treatments for CKD possess anti-inflammatory properties that might contribute to their previously established clinical benefits, including renin-angiotensin-aldosterone system inhibitors, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocortico...
Katherine R. Tuttle, Mehmet Kanbay, Radica Z. Alicic et al.· Nature Reviews Nephrology· 1 citation
An overview of the key signaling pathways and molecular mediators that underlie typical pathophysiological processes in diabetic kidney disease is presented and central role of transforming growth factor-beta in activating various signaling pathways is noted.
O. A. Nagibovich, A. L. Kovalenko, O. S. Ketlinskaya· Nephrology (Saint-Petersburg...· 0 citations
The present review attempts to discuss the different stages of DN, the pathophysiological mechanisms involved in DN development and progression, and potential biomarkers and therapeutic approaches for the effective management of DN.
Kuldip Vyas, Abu Sufiyan Chhipa, Ayushi Chauhan et al.· Discover Molecules· 0 citations
BACKGROUND
Chronic kidney disease (CKD) causes millions of deaths and is a known risk factor for the development of other diseases. CKD has been associated with lung injury characterized by neutrophil infiltration and edema. Despite evidence that the lungs are distant organs affected in CKD, there is no treatment to im...
Bruna Barcelos de Simas, Maria Eduarda Sandin Milani Schütz, Gustavo Ferreira-Alves et al.· Biochemical and Biophysical...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.